n.a. (NEOP)

0.00
OTC BB
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange OTC BB
Shares Outstanding 3.00M
Div & Yield N.A. (N.A)
Neoprobe Announces Second Quarter 2011 Results

Neoprobe Announces Second Quarter 2011 Results

Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced consolidated results for the second quarter of 2011 and for the six-month period...

Neoprobe 2nd Quarter 2011 Earnings And Business Update Conference Call Invitation

Neoprobe 2nd Quarter 2011 Earnings And Business Update Conference Call Invitation

Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced it would report its financial results for the second quarter of 2011 on ...

Neoprobe Comments On Regulatory Approval For Sulfur Colloid Injection

Neoprobe Comments On Regulatory Approval For Sulfur Colloid Injection

On Friday, July 22, 2011, it was disclosed in a private company press release that the U.

Neoprobe Establishes European Business Unit

Neoprobe Establishes European Business Unit

Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that it has established a European business unit to address EU development and...

10 Biotech Trades for Second Half of 2011

10 Biotech Trades for Second Half of 2011

These trades could represent a watershed moment in the lifeline of a biotech company.

Biotech Stock Mailbag: Live Chat

Biotech Stock Mailbag: Live Chat

TheStreet's biotech columnist Adam Feuerstein is holding a live, interactive discussion about biotech stock investing.

Neoprobe Files Response To Citizen Petition

Neoprobe Files Response To Citizen Petition

Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that a formal response has been filed to a Citizen Petition submitted to the Food...

Neoprobe v. Short Seller Over Lymphoseek

Neoprobe v. Short Seller Over Lymphoseek

A hedge fund manager has filed a citizens petition seeking the stop FDA from reviewing Neoprobe's lymph node mapping agent.

Phase 3 Lymphoseek (Tilmanocept) Study Results Featured At Society Of Nuclear Medicine Annual Meeting

Phase 3 Lymphoseek (Tilmanocept) Study Results Featured At Society Of Nuclear Medicine Annual Meeting

Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that full results from the NEO3-05 study, demonstrating Lymphoseek ® ...

Neoprobe Disputes Premise Of Citizens Petition

Neoprobe Disputes Premise Of Citizens Petition

Neoprobe Corporation acknowledges that a Citizen’s Petition has been filed with the U.

ASCO Presentations Reinforce Lymphoseek Clinical Development Approach And Regulatory Pathway

ASCO Presentations Reinforce Lymphoseek Clinical Development Approach And Regulatory Pathway

Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that, following the presentation of full the data set from the NEO3-09 clinical...

ASCO 2011 Live Blog: Monday

ASCO 2011 Live Blog: Monday

Real-time coverage of the American Society of Clinical Oncology (ASCO) annual meeting, where investors will be focused on cancer drug stocks.

Investigators Report Full Phase 3 Lymphoseek (Tilmanocept) Study Results At ASCO

Investigators Report Full Phase 3 Lymphoseek (Tilmanocept) Study Results At ASCO

Independent investigators reported today full results from the NEO3-09 study, reaffirming earlier top-line results that showed Lymphoseek ® ( 99mTc-tilmanocept) met all primary and secondary endpoints and...

Neoprobe Names Executive Vice President, Chief Business Officer

Neoprobe Names Executive Vice President, Chief Business Officer

Neoprobe Corporation (NYSE AMEX: NEOP), a diversified developer of innovative diagnostic products, announced today that Thomas Tulip, Ph.

Biotech Stock Mailbag: Fibrocell Science

Biotech Stock Mailbag: Fibrocell Science

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

Neoprobe Announces Sale Of Gamma Detection Device Business To Devicor Medical Products

Neoprobe Announces Sale Of Gamma Detection Device Business To Devicor Medical Products

Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that it has signed a definitive asset purchase agreement to sell its ...

Cancer Stocks on Tap: ASCO Abstract Preview

Cancer Stocks on Tap: ASCO Abstract Preview

A preview of cancer drug stocks to watch in advance of next week's release of ASCO research abstracts.

Neoprobe Announces First Quarter 2011 Results

Neoprobe Announces First Quarter 2011 Results

Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative biomedical surgical oncology products, today announced consolidated results for the first quarter of 2011.

Neoprobe To Present At 10th Annual JMP Securities Research Conference

Neoprobe To Present At 10th Annual JMP Securities Research Conference

First graph, first sentence of release should read: Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that Dr.

Neoprobe 1st Quarter 2011 Earnings Conference Call Invitation

Neoprobe 1st Quarter 2011 Earnings Conference Call Invitation

Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced it would report its financial results for the first quarter of 2011 on Monday,...

Biotech Stock Mailbag: Neoprobe

Biotech Stock Mailbag: Neoprobe

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

Lymphoseek® (Tilmanocept) Meets All Endpoints In NEO3-09 Phase 3 Study

Lymphoseek® (Tilmanocept) Meets All Endpoints In NEO3-09 Phase 3 Study

Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology diagnostic products, today announced top-line results from its Lymphoseek ® (tilmanocept) NEO3-09 study.

Neoprobe Reaches Agreement With Platinum On Board Nominations

Neoprobe Reaches Agreement With Platinum On Board Nominations

Neoprobe Corporation (NYSE Amex: NEOP) announced today that it has reached an agreement with Platinum Montaur Life Sciences, LLC and its affiliate Platinum Partners Value Arbitrage Fund L.

Neoprobe To Present At Needham And Company’s 10th Annual Healthcare Conference

Neoprobe To Present At Needham And Company’s 10th Annual Healthcare Conference

Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that Dr.

Neoprobe Announces Retirement Of David Bupp And Appointment Of Mark Pykett As President And CEO Effective April 15th

Neoprobe Announces Retirement Of David Bupp And Appointment Of Mark Pykett As President And CEO Effective April 15th

Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, announced today that President and Chief Executive Officer (CEO) David Bupp will retire from the...

Neoprobe Shareholder Submits Board Nominations And Files Schedule 13D

Neoprobe Shareholder Submits Board Nominations And Files Schedule 13D

Neoprobe Corporation (NYSE Amex: NEOP) announced today that it received on March 18, 2011 from Platinum Montaur Life Sciences, LLC ("Platinum") a notice attempting to nominate three persons as directors of Neoprobe ...

LifeSci Advisors Announces Investment Opinion On Neoprobe Corporation

LifeSci Advisors Announces Investment Opinion On Neoprobe Corporation

LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Neoprobe Corporation (NYSE Amex: NEOP), a...

Neoprobe Announces 2010 Results With Record Medical Device Sales

Neoprobe Announces 2010 Results With Record Medical Device Sales

Neoprobe Corporation (NYSE Amex: NEOP) today announced its consolidated results for the fourth quarter of 2010 and for the year ended December 31, 2010.

Neoprobe Completes Successful Pre-IND Meeting With FDA On RIGScan CR

Neoprobe Completes Successful Pre-IND Meeting With FDA On RIGScan CR

Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that it has completed a successful pre-IND meeting with the U.

Neoprobe 4th Quarter And Year-End 2010 Earnings Conference Call Invitation

Neoprobe 4th Quarter And Year-End 2010 Earnings Conference Call Invitation

Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced it would report its financial results for the fourth quarter and full year of...